Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Drug Discovery World

SEPTEMBER 15, 2023

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Replicate’s srRNA technology offers the potential for more robust and durable immune responses, and improved tolerability at lower doses than existing mRNA approaches,” said Zelanna Goldberg, CMO of Replicate. “In

Vaccine 130

Vaccine Trials Immune Response Virus 130

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

PLOS: DNA Science

OCTOBER 3, 2024

One of the oldest and most successful immunotherapies is simpler: a tamed version of a classic vaccine, against the infectious disease tuberculosis (TB). “BCG” is the “treatment” vaccine’s technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. The approach worked.

Vaccine 52

Vaccine Immune Response DNA Doctors 52

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

OCTOBER 31, 2023

The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. As we age, our immune system changes and with it our response to vaccines.

Vaccine 130

Vaccine Immune Response Disease Research 130

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus. “An

Vaccine 130

Vaccine Trials Animal Testing Virus 130

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Sugars, such as sucrose are common stabilizers in many vaccines.

Vaccine 79

Vaccine Immune Response Clinical Trials Virus 79

Drug Discovery World

AUGUST 25, 2023

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). In 2022, Schulz’s team also found that people who received at least one influenza vaccine were 40% less likely than their unvaccinated peers to develop AD.

Vaccine 130

Vaccine Medical Schools Immune Response Disease 130

Drug Discovery World

NOVEMBER 4, 2022

New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. However, their previously identified correlates of risk of TB disease were not associated with an increased risk of M.tb

Vaccine 130

Vaccine Immune Response Disease Research 130

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Image: Dr Noushin Jaberolansar and Dr Andrew Young at lab bench.

Vaccine 130

Vaccine Immune Response Virus Engineering 130

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

MARCH 27, 2023

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. With an LDL-lowering vaccine we can potentially offer an option that’s cost-effective, safe, convenient, long-acting, and deployable.”

Vaccine 130

Vaccine Immune Response Trials Clinical Trials 130

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccine 130

Vaccine Immune Response Virus Disease 130

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccine Hospitals Laboratories 52

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The implications of this finding are far-reaching, as it holds the potential to revolutionize vaccine design.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

Drug Discovery World

SEPTEMBER 23, 2024

Zhijian ‘James’ Chen, Professor of Molecular Biology and Director of the Center for Inflammation Research at UT Southwestern Medical Center, has been awarded the Albert Lasker Basic Medical Research Award for his discovery of the cGAS enzyme, which senses invading pathogens and triggers the body’s innate immune system.

Molecular Biology 147

Molecular Biology Immune Response DNA Virus 147

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. microgram or 15-microgram doses of the vaccine candidate, either alone or with an adjuvant.

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

Drug Discovery World

AUGUST 16, 2022

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s Covid-19 booster vaccine that targets two coronavirus variants. . Known as a bivalent vaccine, Spikevax was approved following data that show it triggers a strong immune response against both Omicron (BA.1)

Immune Response 130

Immune Response Vaccine Clinical Trials Virus 130

Drug Discovery World

JANUARY 12, 2024

Perhaps most importantly, a new antibiotic was found that targets a Gram-negative pathogen, mRNA was used as an effective therapy for a rare liver disease, and a common immune cell was found to attack cancer.

Immune Response 130

Immune Response Vaccine RNA Drugs 130

Drug Discovery World

MARCH 26, 2024

It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.

FDA Approval 130

FDA Approval FDA Clinical Trials Immune Response 130

Drug Discovery World

MARCH 23, 2023

The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. Taken together, these findings suggest that SARS-CoV-2 infection damages the CD8+ T cell response.

Immune Response 130

Immune Response Vaccine Virus Research 130

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The virus also increased the number of immunity-boosting white blood cells within the tumours. million of funding for this research project.

Virus 147

Virus Immune Response Vaccine Engineering 147

Drug Target Review

JANUARY 23, 2024

The current shift focuses on enhancing their efficacy by addressing the crucial need for robust T cell responses, an apparent bottleneck for broader impact. Vaccinations against tumour antigens that are shared between tumours, or tumour antigens that arise from mutations unique to individual tumours, represent promising strategies.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

MARCH 17, 2023

Researchers have shown for the first time that malfunctioning behaviour of a type of immune cell is linked to specific symptoms of Long Covid. Normally functioning monocytes, made in the bone marrow, would travel through the blood to the lungs where they surround and kill the virus and boost the immune response.

Immune Response 130

Immune Response Drugs Vaccine Virus 130

Drug Discovery World

JUNE 28, 2023

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has completed enrolment and initial dosing in its Phase I clinical vaccine trial in older adults. However, invasive GBS disease infections in the elderly population are continuously increasing.

Clinical Trials 130

Clinical Trials Trials Vaccine Immune Response 130

Drug Discovery World

JANUARY 3, 2023

The commencement of the trial triggers a $5 million milestone payment to RQ Bio and will enable the company to execute its four scientific programmes focused on viral diseases. .

Immune Response 130

Immune Response Clinical Trials Vaccine Licensing 130

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About Pfizer: Breakthroughs That Change Patients’ Lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

Drug Target Review

MARCH 1, 2024

This antigen-spreading is critical to long-term protection because tumour often develop with inconsistent antigen expression – equipping the immune response to target many diverse tumour antigens may allow for more complete anti-tumour activity.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

The Pharma Data

SEPTEMBER 4, 2020

The findings have validated confidence in the experimental vaccine, the firm noted. Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, S, prevented severe clinical disease in Syrian golden hamsters when challenged with SARS-CoV-2, the virus that causes COVID-19 in people.

Vaccine 52

Vaccine Immune Response Virus Disease 52

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

Drug Discovery World

JANUARY 17, 2024

5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL). The study examined viral evolution in eight Omicron variants to better understand how the virus has reacted since the introduction of vaccinations.

Virus 130

Virus Vaccine Immune Response Research 130

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. It was, at the time, a very small dosing – a few micrograms combined with an antigen, in other words, an adjuvant to a therapeutic vaccine.

Immune Response 246

Immune Response Therapies Vaccine Production 246